Skip to main content
. 2009 Nov;1(3):183–205. doi: 10.1177/1758834009349119

Table 3.

Randomized phase III trial of sunitinib compared to interferon-α in advanced renal cell cancer patients not having prior systemic therapy [Motzer et al. 2009, 2007b].

Treatment PFS p value OS p value
Sunitinib 11 <0.001 26.4 0.051
Interferon-α 5 21.8

OS, overall survival; PFS, progression-free survival.